Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents?

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 4, 2013, Pages 320-323

  Bartalesi, Filippo ^a   Salomoni, Elena ^b   Cavallo, Annalisa ^a   Corti, Giampaolo ^a,b   Pimpinelli, Nicola ^b   Bartoloni, Alessandro ^a,b   Taliani, Gloria ^c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Etanercept; HCV hepatitis; Peg IFN ; Psoriasis; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ISONIAZID; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RIFAMPICIN; SALICYLIC ACID; VITAMIN D DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; FATTY LIVER; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LATENT TUBERCULOSIS; LIVER BIOPSY; LIVER FIBROSIS; LOBECTOMY; LUNG TUBERCULOSIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHOTOTHERAPY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RELAPSE; TUBERCULIN TEST;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RIBAVIRIN;

EID: 84875436772     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.720026     Document Type: Article

References (23)

1. Yuen M F, Wong R W, Lau C S. S afety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000 ; 18 : 363-8.
2. Guilera M, Forns X, Torras X, Enrì quez J, Coll S, Sol à R, et al. Pre-treatment with prednisolone does not improve the effi cacy of subsequent alpha interferon treatment in chronic hepatitis C. J Hepatol 2000 ; 33 : 135-41.
3. Yurci A, Guven K, Torun E, Gursoy S, Baskol M, Akgun H, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2007 ; 19 : 811-5.
4. Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist ' s view. Minerva Gastroenterol Dietol 2005 ; 51 : 55-61.
5. Taylor C, Burns D A, Wiselka M J. E xtensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 2000 ; 76 : 365-7.
6. Papp KA, Tyring S, Lahfa M, Prinz J, Griffi ths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, effi cacy, and effect of dose reduction. Br J Dermatol 2005 ; 152 : 1304-12.
7. Larrea E, Garcia N, Qian C, Civiera MP, Prieto J. T umor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996 ; 23 : 210-7.
8. Zylbeberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fi brosis and activity. J Hepatol 1997 ; 30 : 185-91.
9. Calabrese L H, Zein N, Vassilopoulos D. S afety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004 ; 63 (Suppl 2) : ii18-24.
10. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, et al. Autoimmune hepatitis associated with infl iximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005 ; 64 : 1519-20.
11. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factoralpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008 ; 35 : 1944-9.
12. Magliocco MA, Gottlieb A B. E tanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004 ; 51 : 580-4.
13. Parke FA, Reveille JD. A nti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004 ; 51 : 800-4.
14. Peterson J R, Hsu FC, Simkin PA, Wener MH. E ffect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003 ; 62 : 1078-82.
15. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007 ; 46 : 97-9.
16. Paradisi A, Caldarola G, Capizzi R, Siciliano M, Annichiarico E, Vecchio FM, et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010 ; 62 : 1067-9.
17. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor in patients with chronic hepatitis C infection: a systematic review. Rheumatology 2011 ; 50 : 1700-11.
18. Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW 3 rd, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol 2010 ; 35 : 397-8.
19. Zein NN ; E tanercept Study Group. E tanercept as an adjuvant to interferon and ribavirin treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005 ; 42 : 315-22.
20. Tellez-Zenteno JF, Negrete-Pulido O, Nunez M, Estanol-Vidal B, Garcia-Ramos G. Peripheral neuropathy during a second cycle of treatment with high doses of interferon-alpha in a patient with hepatitis C, and a review of the literature. Rev Neurol 2002 ; 35 : 644-6.
21. Yu M L, Dai C Y, Huang J E, Nai J H, Lee L P, Hseih M Y, et a l. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 ; 56 : 553-9.
22. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sol á R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 ; 357 : 124-34.
23. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008 ; 47 : 1837-45.